安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- Venetoclax: Uses, Dosage, Side Effects, Warnings - Drugs. com
Venetoclax (brand name Venclexta) may be used to treat chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) in adults, or newly diagnosed acute myeloid leukemia (AML) in those aged 75 years or older, or with other conditions that prevent intensive chemotherapy
- Venetoclax - Wikipedia
Venetoclax, sold under the brand names Venclexta and Venclyxto, is a medication used to treat adults with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or acute myeloid leukemia (AML)
- Venetoclax (oral route) - Mayo Clinic
Venetoclax is used alone or together with other medicines (eg, rituximab) to treat chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, in patients who have received at least one previous treatment
- Venetoclax - NCI - National Cancer Institute
Venetoclax is approved to treat: Acute myeloid leukemia that is newly diagnosed It is used in adults aged 75 years and older or adults who cannot be treated with intensive induction chemotherapy It is given with either azacitidine, decitabine, or low-dose cytarabine
- Venclexta (Venetoclax): Uses in Cancer, Side Effects, Dosages . . .
Venclexta (Venetoclax) is approved for treating chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and acute myeloid leukemia (AML) It is used alone or in combination with other medications depending on the cancer type We’ll explore how Venclexta works for each of these cancers in more detail
- venetoclax (Rx) - Medscape Drugs Diseases
Indicated in combination with azacitidine or decitabine or low-dose cytarabine for treatment in adults (≥75 years) who are newly-diagnosed acute myeloid leukemia (AML) or who have comorbidities
- Venclexta (venetoclax) - Uses, Side Effects, and More
Find patient medical information for Venclexta (venetoclax) on WebMD including its uses, side effects and safety, interactions, pictures, warnings, and user ratings
- Measurable Residual Disease–Guided Therapy for Chronic Lymphocytic . . .
A total of 172 of the 260 participants (66 2%) in the ibrutinib–venetoclax group had undetectable MRD in bone marrow within 2 years, as compared with none of the 263 participants in the
|
|
|